Skip to Content
Merck
All Photos(1)

Documents

06-944

Sigma-Aldrich

Anti-TPOR/c-Mpl Antibody

Upstate®, from rabbit

Synonym(s):

Anti-C-MPL, Anti-MPLV, Anti-THCYT2, Anti-THPOR, Anti-TPOR

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

species reactivity

mouse, human

manufacturer/tradename

Upstate®

technique(s)

immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... MPL(4352)
mouse ... Mpl(17480)

Specificity

glycosylated and unglycosylated TPO receptor/c-Mpl

Immunogen

KLH-conjugated, synthetic peptide corresponding to amino acids 615-628 of human TPO (thrombopoietin) receptor (C-ANHSYLPLSYWQQP)

Application

Anti-TPOR/c-Mpl Antibody is an antibody against TPOR/c-Mpl for use in IP, WB, IH.
Research Category
Signaling
Research Sub Category
Growth Factors & Receptors

Quality

routinely evaluated by immunoblot on RIPA lysates from DAMI cells

Target description

68.5 kDa (calculated)

Physical form

0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide before the addition of glycerol to 30%
Format: Purified
Protein A chromatography

Storage and Stability

2 years at -20°C

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cédric Cleyrat et al.
Traffic (Copenhagen, Denmark), 15(9), 961-982 (2014-06-17)
Myeloproliferative neoplasms (MPNs) are often characterized by JAK2 or calreticulin (CALR) mutations, indicating aberrant trafficking in pathogenesis. This study focuses on Mpl trafficking and Jak2 association using two model systems: human erythroleukemia cells (HEL; JAK2V617F) and K562 myeloid leukemia cells
Reiji Nozaki et al.
Hepatology research : the official journal of the Japan Society of Hepatology, 43(6), 610-620 (2012-11-20)
Liver cirrhosis (LC) is the end stage of chronic liver disease. No definitive pharmacological treatment is currently available. We previously reported that thrombopoietin (TPO) promoted liver regeneration and improved liver cirrhosis by increasing platelet count. TPO is therefore considered to
Norma E Fox et al.
Experimental hematology, 37(4), 495-503 (2009-03-24)
To genetically and functionally characterize mutations of c-Mpl that lead to thrombocytopenia in a child with congenital amegakaryocytic thrombocytopenia. We identified two c-Mpl mutations in a child with clinical features of congenital amegakaryocytic thrombocytopenia, one a previously described mutation in
A R Moliterno et al.
Blood, 94(8), 2555-2561 (1999-10-09)
Recently, we demonstrated a marked reduction in the expression of the thrombopoietin receptor, Mpl, in polycythemia vera (PV) platelets and megakaryocytes using an antiserum against the Mpl extracellular domain. To further examine this abnormality, we raised an antibody to the
Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.
Erickson-Miller, CL; Pillarisetti, K; Kirchner, J; Figueroa, DJ; Ottesen, L; Martin et al.
BMC Cancer null

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service